ATLANTA—Although cyclophosphamide (CYC) may have transformed Wegener’s granulomatosis (WG) from an acute to chronic diagnosis, the risks associated with this drug have pushed rheumatologists and researchers to search for treatment alternatives.
Explore this issueJanuary 2011
Also by this Author
A session at the 2010 ACR/ARHP Annual Scientific Meeting, “Treatment of Wegener’s Granulomatosis/Microscopic Polyangiitis: Understanding and Applying the Data from Recent Clinical Trials,” reviewed what the data have shown so far regarding CYC and other treatment options. [Editor’s Note: This session was recorded and is available via ACR SessionSelect at www.rheumatology.org.]
Philip Seo, MD, assistant professor of rheumatology at the Johns Hopkins Bayview Medical Center in Baltimore, discussed the evolution of WG treatment. For instance, he said longitudinal studies from the National Institutes of Health in 1992 demonstrated the value of CYC. “The good news about [the CYC] regimen is that it works,” Dr. Seo said. “There was 91% marked improvement and 75% complete remission,” he said. However, those improvements come at a cost.
“Forty-two percent of patients have permanent morbidity, 46% have serious infections, and 57% have infertility. There is an 11-fold increased risk of lymphoma and a 33-fold increased risk of bladder cancer. And that’s to say nothing of the risk of steroid-induced damage [often used during treatment]. These are numbers I frequently go over with patients,” Dr. Seo said.